Zobrazeno 1 - 10
of 220
pro vyhledávání: '"Nicolaas Schaap"'
Autor:
Ruben Van Dijck, Ron VAN DER Holt, Ellen Meijer, Timothy Devos, Mette Hazenberg, Marjolein Van Der Poel, Dimitri Breems, Lien Deleu, Nicolaas Schaap, Peter André Willem Te Boekhorst
Publikováno v:
HemaSphere, Vol 7, p e22295e4 (2023)
Externí odkaz:
https://doaj.org/article/e5d03fbe4c4f4682a67cf43439649563
Autor:
Mohamed A. Kharfan-Dabaja, Myriam Labopin, Ali Bazarbachi, Urpu Salmenniemi, Stephan Mielke, Patrice Chevallier, Marie Thérèse Rubio, Marie Balsat, Pietro Pioltelli, Anne-Lise Menard, Gerard Socié, Anne Huynh, Nicolaas Schaap, Arancha Bermúdez Rodríguez, Jan J. Cornelissen, Ibrahim Yakoub-Agha, Mahmoud Aljurf, Sebastian Giebel, Eolia Brissot, Zina Peric, Arnon Nagler, Mohamad Mohty
Publikováno v:
HemaSphere, Vol 6, Iss 11, p e788 (2022)
Outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) for adult acute lymphoblastic leukemia (ALL) have improved over time. Studies have shown that total body irradiation (TBI) is the preferable type of myeloablative conditioning (MAC)
Externí odkaz:
https://doaj.org/article/377096218ba64bf099e65d8a8619db34
Autor:
Johannes Schetelig, Henning Baldauf, Linda Koster, Michelle Kuxhausen, Falk Heidenreich, Liesbeth C. de Wreede, Stephen Spellman, Michel van Gelder, Benedetto Bruno, Francesco Onida, Vinzenz Lange, Carolin Massalski, Victoria Potter, Per Ljungman, Nicolaas Schaap, Patrick Hayden, Stephanie J. Lee, Nicolaus Kröger, Kathy Hsu, Alexander H. Schmidt, Ibrahim Yakoub-Agha, Marie Robin
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Externí odkaz:
https://doaj.org/article/98cab44b6dfb4751a6cc5d0063c00727
Autor:
Ruben A. Mesa, Nicolaas Schaap, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srdan Verstovsek, Shelonitda Rose, Pranav Abraham, Jennifer Lord-Bessen, Derek Tang, Shien Guo, Xiaomei Ye, Claire N. Harrison
Publikováno v:
HemaSphere, Vol 5, Iss 5, p e553 (2021)
Patients with myelofibrosis (MF) experience an array of symptoms that impair health-related quality of life (HRQoL). Fedratinib, an oral, selective Janus-kinase 2 (JAK2) inhibitor, was investigated in the randomized, placebo-controlled, phase III JAK
Externí odkaz:
https://doaj.org/article/628243f171b943f09d35b8a02bf0dbf2
Autor:
Claire N. Harrison, Nicolaas Schaap, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Eric Jourdan, Richard T. Silver, Harry C. Schouten, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srdan Verstovsek, Derek Tang, Pranav Abraham, Jennifer Lord-Bessen, Shelonitda Rose, Shien Guo, Weiqin Liao, Ruben A. Mesa
Publikováno v:
HemaSphere, Vol 5, Iss 5, p e562 (2021)
Myelofibrosis symptoms compromise health-related quality of life (HRQoL). Ruxolitinib can reduce myelofibrosis symptom severity, but many patients discontinue ruxolitinib due to loss of response or unacceptable toxicity. Fedratinib is an oral, select
Externí odkaz:
https://doaj.org/article/6f0f1cefcf9e4277a2ace7bd18ecb259
Autor:
Anna Waszczuk-Gajda, Olaf Penack, Giulia Sbianchi, Linda Koster, Didier Blaise, Péter Reményi, Nigel Russell, Per Ljungman, Marek Trneny, Jiri Mayer, Simona Iacobelli, Guido Kobbe, Christof Scheid, Jane Apperley, Cyrille Touzeau, Stig Lenhoff, Esa Jantunen, Achilles Anagnostopoulos, Laura Paris, Paul Browne, Catherine Thieblemont, Nicolaas Schaap, Jorge Sierra, Ibrahim Yakoub-Agha, Laurent Garderet, Jan Styczynski, Helene Schoemans, Ivan Moiseev, Rafael F. Duarte, Zinaida Peric, Silvia Montoto, Anja van Biezen, Malgorzata Mikulska, Mahmoud Aljurf, Tapani Ruutu, Nicolaus Kröger, Curly Morris, Christian Koenecke, Stefan Schoenland, Grzegorz W. Basak
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 12, p 3541 (2022)
Background: The main goal of this post hoc analysis of the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study was to evaluate the rate of short- and long-term infectious and non-infectious complications occur
Externí odkaz:
https://doaj.org/article/dbb6995090174a7ba0e2956d0c92e9a2
Autor:
Johannes Schetelig, Henning Baldauf, Linda Koster, Michelle Kuxhausen, Falk Heidenreich, Liesbeth C. de Wreede, Stephen Spellman, Michel van Gelder, Benedetto Bruno, Francesco Onida, Vinzenz Lange, Carolin Massalski, Victoria Potter, Per Ljungman, Nicolaas Schaap, Patrick Hayden, Stephanie J. Lee, Nicolaus Kröger, Kathy Hsu, Alexander H. Schmidt, Ibrahim Yakoub-Agha, Marie Robin
Publikováno v:
Frontiers in Immunology, Vol 11 (2021)
Results from registry studies suggest that harnessing Natural Killer (NK) cell reactivity mediated through Killer cell Immunoglobulin-like Receptors (KIR) could reduce the risk of relapse after allogeneic Hematopoietic Cell Transplantation (HCT). Sev
Externí odkaz:
https://doaj.org/article/693c028224f942ae8e114564d060c6a0
Autor:
Xavier Poiré, Myriam Labopin, Johan Maertens, Ibrahim Yakoub-Agha, Didier Blaise, Norbert Ifrah, Gérard Socié, Tobias Gedde-Dhal, Nicolaas Schaap, Jan J. Cornelissen, Stéphane Vigouroux, Jaime Sanz, Lucienne Michaux, Jordi Esteve, Mohamad Mohty, Arnon Nagler
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-10 (2017)
Abstract Background Acute myeloid leukaemia (AML) with 17p abnormalities (abn(17p)) carries a very poor prognosis due to high refractoriness to conventional chemotherapy, and allogeneic stem cell transplantation (allo-SCT) appears as the only potenti
Externí odkaz:
https://doaj.org/article/6a4d07d155f249919081184aad43d067
Autor:
Avichai Shimoni, Myriam Labopin, Bipin Savani, Liisa Volin, Gerhard Ehninger, Jurgen Kuball, Donald Bunjes, Nicolaas Schaap, Stephane Vigouroux, Andrea Bacigalupo, Hendrik Veelken, Jorge Sierra, Matthias Eder, Dietger Niederwieser, Mohamad Mohty, Arnon Nagler
Publikováno v:
Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-10 (2016)
Abstract Background Myeloablative (MAC) and reduced-intensity conditioning (RIC) are established approaches for allogeneic stem cell transplantation (SCT) in acute myeloid leukemia (AML). Most deaths after MAC occur within the first 2 years after SCT
Externí odkaz:
https://doaj.org/article/e4e37a309d4e423dafda6bcf95ed56c7
Autor:
Kirsten Geneugelijk, Kirsten A. Thus, Hanneke W. M. van Deutekom, Jorg J. A. Calis, Eric Borst, Can Keşmir, Machteld Oudshoorn, Bronno van der Holt, Ellen Meijer, Sacha Zeerleder, Marco R. de Groot, Peter A. von dem Borne, Nicolaas Schaap, Jan Cornelissen, Jürgen Kuball, Eric Spierings
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
HLA-mismatches in hematopoietic stem-cell transplantation are associated with an impaired overall survival (OS). The aim of this study is to explore whether the Predicted Indirectly ReCognizable HLA-Epitopes (PIRCHE) algorithm can be used to identify
Externí odkaz:
https://doaj.org/article/04efaf33c183496ba8c5a1597d27ee0a